EZH2 and synovial sarcoma: Consistent with this view, blocking EZH2 activity with small molecules (such as EPZ005687 and tazemetostat) was reported to induce the removal of repressive histone marks and subsequent activation of some tumor suppressor genes usually repressed by SS18-SSX in synovial sarcoma cells [27,28].